New insights into the immunology and evolution of HIV

Cell Research

Volumn 13, Issue 1, 2003, Pages 1-7

  Stebbing, Justin ^a   Patterson, Steve ^a   Gotch, Frances ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

CTL; Evolution; HIV; Immune response; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

BIOLOGICAL MODEL; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MOLECULAR EVOLUTION; PATHOGENICITY; REVIEW; VIROLOGY;

EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL;

EID: 0348046096     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290145     Document Type: Short Survey

References (35)

1. Mathers CD, Sadana R, Salomon JA, Murray CJ, Lopez AD. Healthy life expectancy in 191 countries, 1999. Lancet 2001; 357(9269):685-91.
2. Clark S. Experts predict global devastation due to HIV/AIDS. Lancet 2002; 360(9327):45.
3. Stover J, Walker N, Garnett GP, et al. Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 2002; 360(9326):73-7.
4. Buve A, Bishikwabo-Nsarhaza K, Mutangadura G. The spread and effect of HIV-1 infection in sub-Saharan Africa. Lancet 2002; 359(9322):2011-7.
5. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417(6884):95-8.
6. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13):853-60.
7. Stebbing J, Gazzard B. Resistance in HIV. Journal of HIV therapy 2002; 12(4):181-5.
8. Gerrish P. The rhythm of microbial adaptation. Nature 2001; 413(6853):299-302.
9. Stebbing J, Portsmouth S, Gazzard B. Virus-host interactions. Journal of the Royal College of Obstetricians and Gynaecologists 2002; 9(3):152-9.
10. Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nat Immunol 2001; 2(6):473-5.,p>
11. Ho DD, Huang Y. The HIV-1 vaccine race. Cell 2002; 110(2):135-8.
12. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. Aids 2003; 17(1):F7-F10.,p>
13. Rowland-Jones S, Pinheiro S, Kaul R. New insights into host factors in HIV-1 pathogenesis. Cell 2001; 104(4):473-6.
14. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283(5403):857-60.
15. Allen TM, O' onnor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407(6802):386-90.
16. Lieberman J. Defying death-HIV mutation to evade cytotoxic T lymphocytes. N Engl J Med 2002; 347(15):1203-4.
17. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192(1):63-75.
18. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002; 76(18):9011-23.
19. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8(+) T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3(11):1061-8.
20. Zhang L, Yu W, He T, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298(5595):995-1000.
21. Nassar T, Akkawi S, Bar-Shavit R, et al. Human alpha - defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood 2002; 100(12):4026-32.
22. Malim MH, Emerman M. HIV-1 sequence variation: drift, shift, and attenuation. Cell 2001; 104(4):469-72.
23. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296(5577):2354-60.
24. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002; 296(5572):1439-43.
25. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, Lieberman J. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 2000; 96(9):3094-101.
26. Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001; 98(6):1667-77.
27. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288(5472):1789-96.
28. de Groot NG, Otting N, Doxiadis GG, et al. Evidence for an ancient selective sweep in the MHC class I gene repertoire of chimpanzees. Proc Natl Acad Sci USA 2002; 99(18):11748-53.
29. Santiago ML, Rodenburg CM, Kamenya S, et al. SIVcpz in wild chimpanzees. Science 2002; 295(5554):465.
30. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 1999; 5(5):535-41.
31. Goulder PJ, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412(6844):334-8., p>
32. Stebbing J, Portsmouth S. AIDS Vaccine Research. HIV and AIDS Current Trends 2002; 8(2):15-17.
33. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418(6898):646-50.
34. Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8(7):681-6.
35. Hammer SM. Increasing choices for HIV therapy. N Engl J Med 2002; 346(26):2022-3.